WWL113 is a novel potent and selective inhibitor of Ces3 and Ces1f with IC₅₀ ~0.1 µM in cellular assays. It was discovered by a high throughput screen. Carboxylesterase 3 (Ces3, also known as Ces1d) plays a key role in lipid metabolism (e.g., hydrolyzing long-chain fatty acid esters and thioesters) and promotes lipid storage in adipocytes. Ces3 activity is markedly elevated during adipocyte differentiation. Treatment of two mouse models of obesity/diabetes with WWL113 ameliorates multiple features of metabolic syndrome, including enhancing insulin sensitivity and glucose tolerance and reducing hepatic diacylglycerol species. WWL113 serves as a very useful chemical tool to pharmacologically validate Ces3 as a new therapeutic target. 

How to Use:

• In vitro: WWL113 was used at 10 µM final concentration in various in vitro assays.
• In vivo: WWL113 was administered by oral dosing once a day at a dose of 30-50 mg/kg in the model of diet-induced obesity ordb/db mice. 

Reference: 

• 1. Dominguez E, et al. Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes. (2014) Nat Chem Biol. 10(2):113-21.

Products are for research use only. Not for human use.